Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age ≥ 18 years
• Both males and females will be included
• Negative pregnancy test and effective contraception.
Locations
Other Locations
Egypt
Faculty of Medicine, Mansoura University
RECRUITING
Al Mansurah
Time Frame
Start Date: 2023-02-02
Estimated Completion Date: 2026-02
Participants
Target number of participants: 44
Treatments
No_intervention: Control Group
Mesalamine group, who will receive 1 g mesalamine three times daily for 6 months.
Active_comparator: Pentoxifylline group
The pentoxifylline group will receive 1 g mesalamine three times daily plus pentoxifylline 400 mg two times daily for 6 months.
Related Therapeutic Areas
Sponsors
Leads: Tanta University